| 101 |
24485397 | The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus. | 2014 Mar |
1 |
| 102 |
24547938 | Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. | 2014 Apr |
3 |
| 103 |
24604395 | Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus. | 2014 Jun |
1 |
| 104 |
24612221 | Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. | 2014 Sep |
1 |
| 105 |
24627624 | Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. | 2014 |
2 |
| 106 |
24638989 | Vildagliptin: a review of its use in type 2 diabetes mellitus. | 2014 Apr |
1 |
| 107 |
24640595 | Capillary zone electrophoresis for determination of vildagliptin (a DPP-4 inhibitor) in pharmaceutical formulation and comparative study with HPLC. | 2014 Feb |
1 |
| 108 |
24682379 | Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. | 2014 Jul |
2 |
| 109 |
24802729 | Is there an impact of treatment with DPP-4 inhibitors on lymphocyte subpopulations in type 2 diabetic patients? | 2014 |
1 |
| 110 |
24837407 | Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. | 2014 Jun |
1 |
| 111 |
24939431 | Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. | 2014 Sep |
1 |
| 112 |
24977657 | The dipeptidyl peptidase-4 inhibitor vildagliptin has the capacity to repair β-cell dysfunction and insulin resistance. | 2014 Oct |
1 |
| 113 |
25171159 | DPP-4 inhibitors: pharmacological differences and their clinical implications. | 2014 Sep |
1 |
| 114 |
25204760 | Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release. | 2014 Dec |
1 |
| 115 |
25411599 | Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide. | 2014 Jul |
1 |
| 116 |
25429228 | Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. | 2014 |
1 |
| 117 |
25597711 | [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact]. | 2014 Oct-Dec |
1 |
| 118 |
22882290 | Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. | 2013 Jan |
1 |
| 119 |
23318959 | Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity. | 2013 Jun |
1 |
| 120 |
23323612 | Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? | 2013 Apr |
1 |
| 121 |
23430354 | Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization. | 2013 Feb |
1 |
| 122 |
23431062 | Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. | 2013 |
2 |
| 123 |
23488656 | Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. | 2013 Jul |
1 |
| 124 |
23501107 | A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. | 2013 May 3 |
2 |
| 125 |
23650450 | Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. | 2013 |
1 |
| 126 |
23659561 | Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan. | 2013 Jul |
1 |
| 127 |
23707531 | Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. | 2013 Sep |
1 |
| 128 |
23711060 | [Use of vildagliptin from an internal disease specialists point of view]. | 2013 Apr |
1 |
| 129 |
23782587 | Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. | 2013 Aug |
3 |
| 130 |
23818788 | Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. | 2013 |
1 |
| 131 |
23821355 | Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment. | 2013 Dec |
1 |
| 132 |
23848558 | Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. | 2013 Sep |
1 |
| 133 |
23990203 | Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. | 2013 Dec |
1 |
| 134 |
24068868 | Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. | 2013 |
1 |
| 135 |
24137964 | [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition]. | 2013 |
1 |
| 136 |
24163113 | Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin. | 2013 Dec |
3 |
| 137 |
24185376 | Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme. | 2013 |
4 |
| 138 |
25671081 | The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. | 2013 |
1 |
| 139 |
22051153 | Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. | 2012 Jun |
1 |
| 140 |
22191695 | The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. | 2012 Aug |
1 |
| 141 |
22339447 | Clinical pharmacokinetics and pharmacodynamics of vildagliptin. | 2012 Mar 1 |
8 |
| 142 |
22390829 | Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203. | 2012 Apr |
1 |
| 143 |
22397507 | Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. | 2012 Jun |
1 |
| 144 |
22442825 | Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. | 2012 Mar |
1 |
| 145 |
22442826 | Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. | 2012 Mar |
6 |
| 146 |
22456294 | Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. | 2012 Apr |
2 |
| 147 |
22661900 | Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. | 2012 |
1 |
| 148 |
22672501 | Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. | 2012 Jun 6 |
1 |
| 149 |
22686547 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. | 2012 Aug 1 |
1 |
| 150 |
22690943 | One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. | 2012 Nov |
1 |